In short
BIO89-100, also known as Pegozafermin, is an investigational drug currently being studied in clinical trials for the treatment of Nonalcoholic Steatohepatitis (NASH). These trials aim to evaluate the safety, efficacy, and tolerability of BIO89-100 in patients with NASH, including those with compensated cirrhosis. The drug is administered through subcutaneous injections and shows potential in addressing various aspects of NASH, including liver health and metabolic factors.
At a glance
- Drug Name
- BIO89-100 (Pegozafermin)
- Condition Studied
- Nonalcoholic Steatohepatitis (NASH)
- Administration Method
- Subcutaneous Injection
- Dosages Studied
- 15 mg once weekly, 30 mg once weekly, 44 mg once every 2 weeks
- Primary Outcomes
- NASH resolution, Fibrosis improvement
- Secondary Outcomes
- Changes in liver enzymes, lipid levels, body fat composition, and other metabolic markers
- Study Designs
- Open-label, single-dose PK study; Randomized, double-blind, placebo-controlled study
- Safety Monitoring
- Adverse events (AEs), Serious adverse events (SAEs)
What is BIO89-100?
BIO89-100, also known as pegozafermin, is an investigational drug being studied for the treatment of a liver condition called nonalcoholic steatohepatitis (NASH). It is a new medication that is administered through subcutaneous injections, which means it is injected just under the skin.
What condition does BIO89-100 treat?
BIO89-100 is being developed to treat Nonalcoholic Steatohepatitis (NASH). NASH is a serious liver disease characterized by fat accumulation in the liver, inflammation, and liver cell damage. It can lead to scarring of the liver (fibrosis) and, in severe cases, cirrhosis. NASH is not caused by alcohol consumption but is often associated with obesity, diabetes, and high cholesterol levels.
How is BIO89-100 administered?
BIO89-100 is given as a subcutaneous injection. This means the medication is injected just under the skin, typically in areas with more fatty tissue like the abdomen or thigh. The frequency of administration can vary: Once weekly (QW) dosing Once every two weeks (Q2W) dosing The exact dosing schedule and amount will be determined based on the results of ongoing clinical trials.
Current Clinical Trials
There are currently two main clinical trials investigating BIO89-100: Pharmacokinetic (PK) Study: This is an open-label, single-dose study evaluating how BIO89-100 is processed in the body of patients with NASH and compensated cirrhosis (a less severe form of cirrhosis where the liver is damaged but still functioning). Efficacy and Safety Study: This is a larger, randomized, double-blind, placebo-controlled study looking at the effectiveness, safety, and tolerability of BIO89-100 in patients with biopsy-confirmed NASH. This study is testing different doses and dosing schedules of BIO89-100. These trials will help researchers understand how well BIO89-100 works, how safe it is, and how patients tolerate the medication.
How is the effectiveness of BIO89-100 measured?
The effectiveness of BIO89-100 is being evaluated through several measures: Histological improvement: This involves examining liver tissue samples under a microscope to see if there's a reduction in fat, inflammation, and scarring. Fibrosis improvement: Researchers are looking for a decrease in liver scarring without worsening of NASH. Changes in liver enzymes: Specifically, they're monitoring levels of ALT (alanine transaminase), an enzyme that can indicate liver damage when elevated. Improvements in fat content: This is measured using a special type of MRI called MRI-PDFF (Magnetic Resonance Imaging - Proton Density Fat Fraction). Changes in blood markers: Including triglycerides, cholesterol levels, and other indicators of liver health and metabolic function. These measures help determine if BIO89-100 is effectively treating NASH and improving overall liver health.
Safety and Tolerability
An important aspect of the clinical trials is to evaluate the safety and tolerability of BIO89-100. This includes: Monitoring the frequency and severity of side effects (adverse events) Tracking any serious adverse events Recording how many patients discontinue the treatment due to side effects This information helps researchers understand the overall safety profile of BIO89-100 and determine if the benefits outweigh any potential risks.
Potential Benefits of BIO89-100
While the full results of the clinical trials are not yet available, BIO89-100 is being studied for its potential to: Resolve or improve NASH without worsening liver fibrosis Decrease liver fibrosis without worsening NASH Improve liver fat content Lower levels of liver enzymes, indicating reduced liver damage Improve blood lipid profiles (triglycerides, LDL cholesterol) Potentially improve blood sugar control (as measured by HbA1c) These potential benefits could make BIO89-100 a valuable treatment option for patients with NASH, a condition for which there are currently limited effective treatments available.